G

Genentech

Biotech firm creating medicines via R&D

Partnership & Access Liaison - Neurological Rare Disease, Retina Gene Therapy

Full-TimeUpdated Deadline 11/6/26
$136.3k - $253.1k+ Incentive compensation
Senior
Bachelor's
United States
In PersonField-based across the United States; requires approximately 30–50% travel, including possible overnight travel and weekends.
Medical, Clinical & VeterinaryClinical Support & Patient Administration

About the job

Requirements
  • A Bachelor's degree is required.
  • Clinical experience with patients is required.
  • Bilingual proficiency in English and Spanish is required, including the ability to communicate effectively with patients and caregivers in both languages.
  • At least 5 years of field experience in patient services, reimbursement, or pharmaceuticals is required.
  • Direct experience supporting patients is required, with the ability to connect empathetically with individuals and families facing difficult diagnoses.
  • Knowledge of and adherence to HIPAA, FDA, and internal compliance guidelines are required.
  • Ability to collaborate with case managers and account managers, handle difficult patient cases, and respond promptly to prevent treatment lapses is required.
  • Must reside within NY, NJ, MA, CT, PA, RI, MD, DE, DC, VA, NC, SC, GA, or FL, with reasonable access to a major commercial airport.
  • A valid driver's license is required.
Responsibilities
  • For Retina Gene Therapy, serve as the main non-clinical point of contact for patients and families after enrollment.
  • Work with patients to navigate the steps required to access therapy after a treatment decision has been made.
  • Coordinate logistical needs, including assessing and offering solutions for patient and caregiver travel, lodging, and meals.
  • Guide patients in selecting appropriate treatment centers.
  • Facilitate and provide information about the Benefits Investigation and Prior Authorization process, which is driven by the Treatment Center.
  • Educate patients and Treatment Center staff on payer policies, procedures, and available approved resources.
  • Educate patients on the treatment process and available Spark services.
  • Collaborate with internal teams, including Market Access and Account Executives, and external stakeholders, including treatment centers and physicians, to resolve patient access barriers.
  • For NRD, provide on-label education to patients, caregivers, and the community about the NRD product, including its clinical profile, dosing, and administration.
  • Communicate Genentech-specific reimbursement programs, policies, and resources.
  • Maintain regular patient contact to identify and resolve on-label insurance, pharmacy, and other reimbursement challenges.
  • Provide patient-specific reimbursement navigation and empower customers to resolve access issues.
  • Educate customers and partners on national, regional, and local payer coverage policies.
  • Engage with and support local advocacy chapters through programming, events, and sponsorships.
  • Establish Genentech as a trusted partner in the neurology rare disease community.
  • Adhere to laws, company policies including Luxturna and NRD Business Guidance, HIPAA guidelines, and regulatory requirements.
  • Partner with internal field-facing roles and home office teams, and with external stakeholders.
  • Track all patient interactions using approved tools, attend team meetings, and meet administrative expectations.
  • Obtain and maintain proficiency in disease-state and product knowledge for both therapeutic areas.
  • Travel approximately 30–50% of the time, including some overnight and weekend travel; the preferred qualifications also state ability to travel up to 60%.
Desired Qualifications
  • Experience with managed care, rare or orphan diseases, and institutional or account management is preferred.
  • An RN, related clinical experience, or case management experience is strongly preferred.
  • A deep understanding of the payer landscape and pharmaceutical reimbursement processes is preferred.
  • Strong communication and presentation skills are preferred.
  • Ability to travel up to 60% of the time is preferred.

About the company

Genentech conducts extensive biotechnology R&D to discover medicines and therapies for unmet medical needs. Its treatments, including biologics, are developed, approved, and marketed to patients through healthcare providers and systems. It differentiates itself by a large research footprint, a strong patent portfolio, and multiple FDA Breakthrough Therapy Designations that speed promising therapies to patients. The goal is to advance medical science and deliver high-quality, effective therapies while balancing access and affordability for patients and the medical community.

Company Size

10,001+

Company Stage

IPO

Headquarters

San Francisco, California

Founded

1976

Get referred to Genentech

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Hillsboro broke ground September 28, 2026 on a $750 million device fill-finish plant.
  • The project adds 250 jobs and strengthens U.S. supply for oncology, neurology, immunology.
  • Roche opened Boston's CVRM Innovation Center on September 17, 2026, expanding discovery capacity.

What critics are saying

  • September 2026 layoffs cut 265 South San Francisco jobs, ending a 40-year plant.
  • June and July 2026 cuts removed 103 gRED roles, signaling continuing research retrenchment.
  • Vabysmo concentration leaves Genentech vulnerable to a retinal franchise reversal by 2027.

What makes Genentech unique

  • Roche-backed Genentech pairs drug discovery with manufacturing, diagnostics, and global commercialization at scale.
  • Vabysmo delivered real-world eye-disease data on September 30, 2026 across 28 countries.
  • The September 24, 2026 Earendil deal shows Genentech still commands elite biotech partners.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Performance Bonus
  • Relocation Assistance

Growth & Insights and Company News

6 month growth

0%

1 year growth

-3%

2 year growth

-3%
Associated Press
Oct 16th, 2026
FDA approves Genentech's Enspryng as first at-home injection for thyroid eye disease

Genentech, a member of the Roche Group, said the US Food and Drug Administration (FDA) has approved Enspryng for adults with thyroid eye disease (TED). It is the first and only at-home subcutaneous treatment for the condition, and patients or caregivers can give it after training. In the Phase III SatraGO-2 trial, 52.9% of active TED patients on Enspryng had a proptosis response, against 23.4% on placebo. Diplopia fell in 60.7% versus 25.8%. The sister trial, SatraGO-1, missed its primary endpoint at week 24. No new safety signals emerged. The approval, which followed a priority review, is Enspryng's second indication after neuromyelitis optica spectrum disorder in 2020. The FDA is also reviewing it for MOGAD, with a decision expected in January 2027.

The Hindu BusinessLine
Oct 14th, 2026
Biocon inks global patent settlement pact with Genentech for breast cancer drug Pebrilzo.

Biocon inks global patent settlement pact with Genentech for breast cancer drug Pebrilzo. By PTI. Updated - October 14, 2026 at 02:43 PM. Biocon Ltd on Wednesday said it has entered into a global settlement and license agreement with Genentech for breast cancer drug Pebrilzo, its biosimilar to the reference product Perjeta (Pertuzumab). The patent settlement agreement resolves all pending disputes between the two companies across multiple jurisdictions, including the US and Canada, the biopharmaceutical company said in a regulatory filing on Wednesday. Under the terms of the agreement, Biocon is cleared to launch Pebrilzo in the European Union and the United Kingdom in the first quarter of calendar year (CY) 2027, followed by a launch in the US in the third quarter of CY 2028. For other rest of the world markets, the launch is slated for 2026-2028, or earlier under certain circumstances. THIS AD SUPPORTS OUR JOURNALISM. SUBSCRIBE FOR MINIMAL ADS.

PR Newswire
Oct 13th, 2026
2026 Patient Innovators Awards winners announced at Courier Health's annual Summit.

2026 Patient Innovators Awards winners announced at Courier Health's annual Summit. Oct 13, 2026, 09:00 ET Honorees celebrated as biopharma gathered in New York City to chart the future of the patient experience NEW YORK, Oct. 13, 2026 /PRNewswire/ - Courier Health, the leading technology company for managing patient experiences, today announced the winners of the second annual Patient Innovators Awards, which recognize the biopharma teams and leaders going above and beyond to improve patient access, innovation, and overall outcomes. Winners were announced live on October 6th at the third annual Patient Innovators Summit in New York City. The invite-only event brought together Patient Services, Access & Reimbursement, and Commercial IT & Analytics leaders from more than 75 biopharma companies. Together, attendees represented more than 100 disease states and roughly 35 million patients with previously unmet needs. Four teams and one individual were recognized for driving innovation and measurably improving the patient experience: * Rare Disease Champions of the Year: KalVista, a Company of Chiesi Group * Patient Services Team of the Year: Priovant Therapeutics * Field Access Team of the Year: UCB, Inc. * Patient Champion of the Year: Rob Chuba, Alkermes * Patient Innovators of the Year: Bristol Myers Squibb's CAR T-cell therapy Patient Access Support Services (PASS) team "Being named Patient Services Team of the Year is a testament to the team and program we're building," said Lee Liberator, Vice President of Patient Services and Reimbursement at Priovant Therapeutics. "We've built a unique program centered around what patients actually need from us, and we're proud to be recognized for our commitment to innovating and championing a better patient experience." In his opening keynote, Danny Sigurdson, Founder and CEO of Courier Health, described the moment as a fork in the road. As manufacturers take greater internal control of their programs, data ownership, outcomes-based measurement, and AI-enabled workflow innovation have become critical. Organizations that invest in the right foundation will gain greater operational leverage to focus on their core competency - supporting patients and providers - while those that don't will fall further behind. "This year's Patient Innovators Awards winners are proof that a better path, and a brighter future, is already being built," said Danny Sigurdson. "These teams and our individual Patient Champion of the Year aren't afraid to challenge the status quo and rethink how their programs run. They never lose sight of the patient, and it's an honor to recognize their contributions." This year's Patient Innovators Summit featured 11 industry speakers from companies including Alkermes, Beren Therapeutics, Corcept Therapeutics, Compass Pathways, Dyne Therapeutics, Genentech, and Tarus Pharmaceuticals. The audience also heard a powerful firsthand story from Mark Dant, rare disease advocate and Volunteer Executive Director for the Ryan Foundation. About Courier Health Courier Health is a New York City-based technology company on a mission to improve the patient experience for hundreds of millions of people living with a chronic condition or rare disease. The company develops and delivers the fastest-growing patient experience solution for the life sciences industry. Companies that choose Courier Health are achieving double-digit improvements to patient starts, time-to-start and ongoing adherence to life-altering therapies. As host of the invite-only Patient Innovators Summit and publisher of The State of Patient-Centricity in Biopharma report, Courier Health is backed by leading investors, including Oak HC/FT, Norwest and Work-Bench. Follow Courier Health on LinkedIn and learn more at www.courierhealth.com. SOURCE Courier Health

Yahoo Finance
Oct 9th, 2026
FDA approves Tecentriq for stage III colon cancer, cutting recurrence risk by 50%

The FDA has approved Genentech's Tecentriq in combination with a fluoropyrimidine and oxaliplatin for adjuvant treatment of stage III deficient DNA mismatch repair colon cancer. This marks Tecentriq's twelfth indication in the US. The approval follows results from the Phase III ATOMIC study, published in The New England Journal of Medicine. The trial showed Tecentriq plus chemotherapy reduced the risk of disease recurrence or death by 50% compared to chemotherapy alone. The 36-month disease-free survival was 86% with Tecentriq combined with mFOLFOX6, versus 76% with mFOLFOX6 alone. Nearly 25% of colon cancers are diagnosed at stage III. Almost one in three patients with stage III colon cancer experience recurrence within five years. This represents the first approved adjuvant immunotherapy regimen for this patient population.

Pharma Journalist
Oct 7th, 2026
Alector licenses Parkinson's drug program to Genentech for $1.27B.

Alector licenses Parkinson's drug program to Genentech for $1.27B. On Oct 7, 2026 Alector has entered into an exclusive global licensing agreement with Genentech, a member of the Roche Group, to develop and commercialize AL050, an investigational therapy designed to treat a key cause of neurodegeneration linked to Parkinson's disease. Under the agreement, Genentech will receive worldwide rights to AL050, which is designed to address deficiencies in glucocerebrosidase (GCase), an enzyme linked to Parkinson's disease, particularly in people carrying mutations in the GBA1 gene. Alector will receive $100 million upfront from Genentech and could receive up to an additional $1.17 billion in development, regulatory and commercial milestone payments. The company will also be eligible for tiered royalties based on net sales. AL050 combines an engineered version of the GCase enzyme with Alector's proprietary Alector Brain Carrier (ABC) technology. The approach is designed to help the therapy cross the blood-brain barrier and reach the brain, where GCase deficiency can cause harmful lipids to build up in nerve cells. The therapy is intended to break down glucosylsphingosine and glucosylceramide, two lipids that can accumulate when GCase activity is reduced. Alector believes reducing this buildup could help improve cell function and potentially slow the progression of Parkinson's disease. GCase deficiency is increasingly being studied as an important driver of Parkinson's disease. People with GBA1 mutations are at higher risk of developing the disease, although GCase-related mechanisms may also play a role in patients without these mutations. Under the partnership, Genentech will take responsibility for the development, regulatory work, manufacturing and commercialization of AL050 across all potential indications. Alector will retain ownership of its ABC technology and continue using the platform in its wholly owned pipeline. Alector CEO Arnon Rosenthal said the company designed AL050 to address two major challenges in treating GCase deficiency: developing an enzyme with strong and lasting activity and delivering it effectively into the brain. The deal also gives Alector additional resources to advance its other programs. The company said the partnership extends its cash runway into 2029. Alector plans to use these resources to advance its subcutaneously delivered, brain-enabled anti-Aβ antibody program toward multi-cohort clinical data in Alzheimer's disease. The company also plans to move its brain-enabled tau siRNA and alpha-synuclein siRNA programs through IND-enabling studies and toward regulatory filings. The collaboration marks another major step in Genentech's efforts to develop new treatments for Parkinson's disease, while giving Alector the financial support to continue developing therapies targeting neurodegenerative diseases.